JP2021523200A - Ｍａｇｌ阻害剤 - Google Patents
Ｍａｇｌ阻害剤 Download PDFInfo
- Publication number
- JP2021523200A JP2021523200A JP2020564158A JP2020564158A JP2021523200A JP 2021523200 A JP2021523200 A JP 2021523200A JP 2020564158 A JP2020564158 A JP 2020564158A JP 2020564158 A JP2020564158 A JP 2020564158A JP 2021523200 A JP2021523200 A JP 2021523200A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- solvate
- formula
- acceptable salt
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 CCC[C@](C1[C@](**)C1[C@@]1CC)C1=CCCC Chemical compound CCC[C@](C1[C@](**)C1[C@@]1CC)C1=CCCC 0.000 description 7
- HXTWKHXDFATMSP-UHFFFAOYSA-N Oc1c(C=O)ccc(Br)c1 Chemical compound Oc1c(C=O)ccc(Br)c1 HXTWKHXDFATMSP-UHFFFAOYSA-N 0.000 description 2
- HJQNTNCVLOPGPG-UHFFFAOYSA-N CC(C)(C(Cl)=O)Oc1cc(C(F)(F)F)ccc1CN(CC1)CCN1C(OC(C(F)(F)F)C(F)(F)F)=O Chemical compound CC(C)(C(Cl)=O)Oc1cc(C(F)(F)F)ccc1CN(CC1)CCN1C(OC(C(F)(F)F)C(F)(F)F)=O HJQNTNCVLOPGPG-UHFFFAOYSA-N 0.000 description 1
- GONYXMWENPVIFB-UHFFFAOYSA-N CC(C)(C(NS(C1CC1)(=O)=O)=O)Oc1cc(C(F)(F)F)ccc1CN(CC1)CCN1C(OC(C(F)(F)F)C(F)(F)F)=O Chemical compound CC(C)(C(NS(C1CC1)(=O)=O)=O)Oc1cc(C(F)(F)F)ccc1CN(CC1)CCN1C(OC(C(F)(F)F)C(F)(F)F)=O GONYXMWENPVIFB-UHFFFAOYSA-N 0.000 description 1
- PMNYHCJQBBHOKK-UHFFFAOYSA-N CC(C)(C)OC(N1CCN(Cc(c(O)c2)ccc2Br)CC1)=O Chemical compound CC(C)(C)OC(N1CCN(Cc(c(O)c2)ccc2Br)CC1)=O PMNYHCJQBBHOKK-UHFFFAOYSA-N 0.000 description 1
- SNWXXYBPEBUWOS-UHFFFAOYSA-N CC(C)(C)OC(N1CCN(Cc2ccc(C(F)(F)F)cc2OCC(C)(C)C(O)=O)CC1)=O Chemical compound CC(C)(C)OC(N1CCN(Cc2ccc(C(F)(F)F)cc2OCC(C)(C)C(O)=O)CC1)=O SNWXXYBPEBUWOS-UHFFFAOYSA-N 0.000 description 1
- MAWSUYVJXRKPDS-UHFFFAOYSA-N CC(C)(COc1cc(C(F)(F)F)cc(CN(CC2)CCN2C(OC(C(F)(F)F)C(F)(F)F)=O)c1)C(O)=O Chemical compound CC(C)(COc1cc(C(F)(F)F)cc(CN(CC2)CCN2C(OC(C(F)(F)F)C(F)(F)F)=O)c1)C(O)=O MAWSUYVJXRKPDS-UHFFFAOYSA-N 0.000 description 1
- AQZXFHIOAOCGCY-UHFFFAOYSA-N CC(CC(CCOCCF)=C1)C(CN2CCNCC2)=C1OC(C)(C)C(O)=O Chemical compound CC(CC(CCOCCF)=C1)C(CN2CCNCC2)=C1OC(C)(C)C(O)=O AQZXFHIOAOCGCY-UHFFFAOYSA-N 0.000 description 1
- GCBKEGKWMHWYFM-UHFFFAOYSA-N CCCC[Sn](CCCC)(CCCC(C)C)c1ncc[o]1 Chemical compound CCCC[Sn](CCCC)(CCCC(C)C)c1ncc[o]1 GCBKEGKWMHWYFM-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N CN1CCNCC1 Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- NWDHTEIVMDYWQJ-UHFFFAOYSA-N Oc1c(C=O)cccc1F Chemical compound Oc1c(C=O)cccc1F NWDHTEIVMDYWQJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyridine Compounds (AREA)
- Epoxy Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671985P | 2018-05-15 | 2018-05-15 | |
| US62/671,985 | 2018-05-15 | ||
| PCT/US2019/032289 WO2019222266A1 (en) | 2018-05-15 | 2019-05-14 | Magl inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021523200A true JP2021523200A (ja) | 2021-09-02 |
| JP2021523200A5 JP2021523200A5 (enExample) | 2022-06-01 |
Family
ID=68534223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564158A Ceased JP2021523200A (ja) | 2018-05-15 | 2019-05-14 | Ｍａｇｌ阻害剤 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US10570106B2 (enExample) |
| EP (1) | EP3793547A4 (enExample) |
| JP (1) | JP2021523200A (enExample) |
| KR (1) | KR20210010475A (enExample) |
| CN (1) | CN112088001A (enExample) |
| AR (1) | AR115092A1 (enExample) |
| AU (1) | AU2019271123A1 (enExample) |
| BR (1) | BR112020000863A2 (enExample) |
| CA (1) | CA3097063A1 (enExample) |
| CL (1) | CL2020002927A1 (enExample) |
| CO (1) | CO2020013550A2 (enExample) |
| CR (1) | CR20200545A (enExample) |
| DO (1) | DOP2020000207A (enExample) |
| EA (1) | EA202092586A1 (enExample) |
| GE (2) | GEP20227443B (enExample) |
| JO (1) | JOP20200276A1 (enExample) |
| MA (1) | MA52635A (enExample) |
| MX (1) | MX2020012158A (enExample) |
| NI (1) | NI202000080A (enExample) |
| PE (1) | PE20211385A1 (enExample) |
| PH (1) | PH12020551934A1 (enExample) |
| SG (1) | SG11202011228TA (enExample) |
| TW (1) | TW201946906A (enExample) |
| WO (1) | WO2019222266A1 (enExample) |
| ZA (1) | ZA202006327B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9487495B2 (en) | 2012-01-06 | 2016-11-08 | The Scripts Research Institute | Carbamate compounds and of making and using same |
| JP7042804B2 (ja) | 2016-09-19 | 2022-03-28 | ルンドベック ラ ホーヤ リサーチ センター，インク． | ピペラジンカルバメート、及びその製造と使用の方法 |
| KR102551319B1 (ko) | 2018-05-14 | 2023-07-05 | 길리애드 사이언시즈, 인코포레이티드 | Mcl-1 억제제 |
| KR20210010475A (ko) | 2018-05-15 | 2021-01-27 | 룬드벡 라 졸라 리서치 센터 인코포레이티드 | Magl 저해제 |
| CA3096777A1 (en) | 2018-06-27 | 2020-02-02 | F. Hoffmann-La Roche Ag | Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2 |
| CN112638430B (zh) | 2018-06-27 | 2023-05-16 | 豪夫迈·罗氏有限公司 | 放射性标记的大麻素受体2配体 |
| JP7478672B2 (ja) | 2018-06-27 | 2024-05-07 | エフ． ホフマン－ラ ロシュ アーゲー | カンナビノイド受容体２の阻害剤としての新規なアゼチジン置換ピリジン及びピラジン化合物 |
| MA54827A (fr) * | 2019-01-25 | 2022-05-04 | H Lundbeck As | Méthodes de traitement d'une maladie à l'aide d'inhibiteurs de magl |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| KR20220101095A (ko) * | 2019-11-15 | 2022-07-19 | 하. 룬드벡 아크티에셀스카브 | Magl 억제제의 결정형 |
| AU2020391106B2 (en) | 2019-11-26 | 2024-03-21 | Gilead Sciences, Inc. | Processes and intermediates for preparing MCL1 inhibitors |
| IL297470A (en) | 2020-04-21 | 2022-12-01 | H Lundbeck As | Synthesis of a monoacylglycerol lipase inhibitor |
| WO2022108984A1 (en) | 2020-11-19 | 2022-05-27 | Gilead Sciences, Inc. | Processes and intermediates for preparing macrocyclic mcl1 inhibitors |
| EP4198023A1 (en) | 2021-12-16 | 2023-06-21 | Basf Se | Pesticidally active thiosemicarbazone compounds |
| CA3242372A1 (en) | 2021-12-29 | 2023-07-06 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
| US20250197358A1 (en) | 2022-02-17 | 2025-06-19 | Basf Se | Pesticidally active thiosemicarbazone compounds |
| EP4665718A1 (en) | 2023-02-13 | 2025-12-24 | Apogee Pharmaceuticals, Inc. | Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015508407A (ja) * | 2012-01-06 | 2015-03-19 | アビデ セラピューティクス，インク． | カルバメート化合物およびその製造および使用 |
| WO2016149401A2 (en) * | 2015-03-18 | 2016-09-22 | Abide Therapeutics, Inc. | Piperazine carbamates and methods of making and using same |
| WO2018053447A1 (en) * | 2016-09-19 | 2018-03-22 | Abide Therapeutics, Inc. | Piperazine carbamates and methods of making and using same |
| JP2019537596A (ja) * | 2016-11-16 | 2019-12-26 | ルンドベック ラ ホーヤ リサーチ センター，インク． | Ｍａｇｌ阻害剤の結晶形態 |
| JP2020532547A (ja) * | 2017-08-29 | 2020-11-12 | ルンドベック ラ ホーヤ リサーチ センター，インク． | スピロ環化合物並びにその作製及び使用方法 |
| JP7042547B2 (ja) * | 2016-11-16 | 2022-03-28 | ルンドベック ラ ホーヤ リサーチ センター，インク． | Ｍａｇｌ阻害剤 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1593586A (enExample) | 1967-10-17 | 1970-06-01 | ||
| JPS6183073A (ja) | 1984-10-01 | 1986-04-26 | Oki Electric Ind Co Ltd | 印字装置の用紙送り方法 |
| WO1989011794A1 (fr) | 1988-06-07 | 1989-12-14 | Rikagaku Kenkyusho | Inhibiteur de la croissance de plantes |
| WO1993011097A1 (en) | 1991-11-27 | 1993-06-10 | E.I. Du Pont De Nemours And Company | Herbicidal acylated amino-(phenyl- or pyridinyl- or thienyl-)-phenyl derivatives |
| WO1995017439A2 (en) | 1993-12-22 | 1995-06-29 | Shell Internationale Research Maatschappij B.V. | Process for preparing carbamates |
| JP2000500448A (ja) | 1995-11-15 | 2000-01-18 | ゼネカ リミテッド | 除草性置換ピラゾール化合物 |
| WO1998000408A1 (en) | 1996-07-02 | 1998-01-08 | Novartis Ag | N-phenylimino heterocyclic derivatives and their use as herbicides |
| RU2167150C2 (ru) | 1998-03-25 | 2001-05-20 | Фокин Александр Васильевич | Полифторалкил-n-арилкарбаматы, обладающие антимикробной активностью |
| DE60042338D1 (de) | 1999-10-04 | 2009-07-16 | Univ New Jersey Med | TAR RNA bindende Peptide |
| EP1201298A1 (en) | 2000-10-24 | 2002-05-02 | Urea Casale S.A. | Carbamate condensation unit |
| DE10348022A1 (de) | 2003-10-15 | 2005-05-25 | Imtm Gmbh | Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| FR2864080B1 (fr) | 2003-12-23 | 2006-02-03 | Sanofi Synthelabo | Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique |
| WO2005063698A1 (en) | 2003-12-31 | 2005-07-14 | Council Of Scientific & Industrial Research | Process for preparing carbamates |
| TW200531694A (en) | 2004-02-18 | 2005-10-01 | Astrazeneca Ab | Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists |
| CN101830899A (zh) | 2004-12-23 | 2010-09-15 | 霍夫曼-拉罗奇有限公司 | 杂环氨基甲酸酯衍生物,它们的制备及作为药剂的应用 |
| NZ590148A (en) | 2004-12-30 | 2012-04-27 | Janssen Pharmaceutica Nv | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase |
| EP1948630A2 (en) | 2005-11-05 | 2008-07-30 | AstraZeneca AB | Novel compounds |
| JP2009523729A (ja) | 2006-01-13 | 2009-06-25 | ピーティーシー セラピューティクス，インコーポレーテッド | Ｃ型肝炎の治療方法 |
| HRP20150642T1 (hr) | 2006-12-22 | 2015-08-14 | Astex Therapeutics Limited | BICIKLIÄŚKE HETEROCIKLIÄŚKE TVARI KAO INHIBITORI FGFR-a |
| WO2008106047A2 (en) | 2007-02-26 | 2008-09-04 | Kosan Biosciences Incorporated | Carbamate compounds |
| US8188098B2 (en) | 2008-05-19 | 2012-05-29 | Hoffmann-La Roche Inc. | GPR119 receptor agonists |
| JP2011528368A (ja) | 2008-07-16 | 2011-11-17 | シェーリング コーポレイション | 二環式ヘテロ環誘導体およびｇｐｃｒモジュレーターとしてのその使用 |
| WO2010056309A2 (en) | 2008-11-14 | 2010-05-20 | The Scripps Research Institute | Methods and compositions related to targeting monoacylglycerol lipase |
| KR20110131302A (ko) | 2009-03-23 | 2011-12-06 | 엠에스디 가부시키가이샤 | 오로라 ａ 선택적 억제 작용을 갖는 신규한 아미노피리딘 유도체 |
| JP2012524800A (ja) | 2009-04-22 | 2012-10-18 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | モノアシルグリセロールリパーゼ阻害剤としてのアゼチジニルジアミド |
| UA107791C2 (en) | 2009-05-05 | 2015-02-25 | Dow Agrosciences Llc | Pesticidal compositions |
| WO2011054795A1 (de) | 2009-11-03 | 2011-05-12 | Bayer Materialscience Ag | Fluorurethane als additive in einer photopolymer-formulierung |
| FR2960875B1 (fr) | 2010-06-04 | 2012-12-28 | Sanofi Aventis | Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique |
| PE20142098A1 (es) | 2012-01-06 | 2015-01-08 | Agios Pharmaceuticals Inc | Compuestos terapeuticamente activos y sus metodos de uso |
| EP2828253A1 (en) | 2012-03-19 | 2015-01-28 | Abide Therapeutics, Inc. | Carbamate compounds and of making and using same |
| JP2014005245A (ja) | 2012-06-26 | 2014-01-16 | Dainippon Sumitomo Pharma Co Ltd | 二環性ピリミジン誘導体を含有する医薬組成物 |
| US9551036B2 (en) | 2013-02-25 | 2017-01-24 | Whitehead Institute For Biomedical Research | Metabolic gene mesenchymal signatures and uses thereof |
| CA2917050A1 (en) | 2013-07-03 | 2015-01-08 | Todd K. Jones | Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof |
| WO2016014975A2 (en) | 2014-07-25 | 2016-01-28 | Northeastern University | Urea/carbamates faah magl or dual faah/magl inhibitors and uses thereof |
| JOP20190105A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| KR20210010475A (ko) | 2018-05-15 | 2021-01-27 | 룬드벡 라 졸라 리서치 센터 인코포레이티드 | Magl 저해제 |
| MA54827A (fr) | 2019-01-25 | 2022-05-04 | H Lundbeck As | Méthodes de traitement d'une maladie à l'aide d'inhibiteurs de magl |
-
2019
- 2019-05-14 KR KR1020207033709A patent/KR20210010475A/ko not_active Ceased
- 2019-05-14 CA CA3097063A patent/CA3097063A1/en active Pending
- 2019-05-14 EA EA202092586A patent/EA202092586A1/ru unknown
- 2019-05-14 GE GEAP201915479A patent/GEP20227443B/en unknown
- 2019-05-14 WO PCT/US2019/032289 patent/WO2019222266A1/en not_active Ceased
- 2019-05-14 AU AU2019271123A patent/AU2019271123A1/en not_active Abandoned
- 2019-05-14 MX MX2020012158A patent/MX2020012158A/es unknown
- 2019-05-14 AR ARP190101283A patent/AR115092A1/es not_active Application Discontinuation
- 2019-05-14 CN CN201980031137.4A patent/CN112088001A/zh active Pending
- 2019-05-14 GE GEAP202215479A patent/GEAP202215479A/en unknown
- 2019-05-14 US US16/412,212 patent/US10570106B2/en not_active Expired - Fee Related
- 2019-05-14 TW TW108116518A patent/TW201946906A/zh unknown
- 2019-05-14 EP EP19803143.7A patent/EP3793547A4/en not_active Withdrawn
- 2019-05-14 SG SG11202011228TA patent/SG11202011228TA/en unknown
- 2019-05-14 BR BR112020000863-0A patent/BR112020000863A2/pt not_active Application Discontinuation
- 2019-05-14 CR CR20200545A patent/CR20200545A/es unknown
- 2019-05-14 MA MA052635A patent/MA52635A/fr unknown
- 2019-05-14 US US17/055,079 patent/US11332453B2/en active Active
- 2019-05-14 JO JOP/2020/0276A patent/JOP20200276A1/ar unknown
- 2019-05-14 JP JP2020564158A patent/JP2021523200A/ja not_active Ceased
- 2019-05-14 PE PE2020001853A patent/PE20211385A1/es unknown
-
2020
- 2020-01-10 US US16/739,642 patent/US11214557B2/en not_active Expired - Fee Related
- 2020-10-12 ZA ZA2020/06327A patent/ZA202006327B/en unknown
- 2020-10-28 CO CONC2020/0013550A patent/CO2020013550A2/es unknown
- 2020-11-10 DO DO2020000207A patent/DOP2020000207A/es unknown
- 2020-11-11 CL CL2020002927A patent/CL2020002927A1/es unknown
- 2020-11-13 NI NI202000080A patent/NI202000080A/es unknown
- 2020-11-13 PH PH12020551934A patent/PH12020551934A1/en unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015508407A (ja) * | 2012-01-06 | 2015-03-19 | アビデ セラピューティクス，インク． | カルバメート化合物およびその製造および使用 |
| WO2016149401A2 (en) * | 2015-03-18 | 2016-09-22 | Abide Therapeutics, Inc. | Piperazine carbamates and methods of making and using same |
| WO2018053447A1 (en) * | 2016-09-19 | 2018-03-22 | Abide Therapeutics, Inc. | Piperazine carbamates and methods of making and using same |
| JP2019537596A (ja) * | 2016-11-16 | 2019-12-26 | ルンドベック ラ ホーヤ リサーチ センター，インク． | Ｍａｇｌ阻害剤の結晶形態 |
| JP7042547B2 (ja) * | 2016-11-16 | 2022-03-28 | ルンドベック ラ ホーヤ リサーチ センター，インク． | Ｍａｇｌ阻害剤 |
| JP2020532547A (ja) * | 2017-08-29 | 2020-11-12 | ルンドベック ラ ホーヤ リサーチ センター，インク． | スピロ環化合物並びにその作製及び使用方法 |
Non-Patent Citations (1)
| Title |
|---|
| JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 139, JPN6023021412, 2017, pages 12390 - 12393, ISSN: 0005070871 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112088001A (zh) | 2020-12-15 |
| NI202000080A (es) | 2021-02-15 |
| US20190352273A1 (en) | 2019-11-21 |
| US20200148653A1 (en) | 2020-05-14 |
| US11214557B2 (en) | 2022-01-04 |
| PE20211385A1 (es) | 2021-07-27 |
| DOP2020000207A (es) | 2021-02-15 |
| CA3097063A1 (en) | 2019-11-21 |
| MA52635A (fr) | 2021-03-24 |
| CR20200545A (es) | 2020-12-17 |
| GEAP202215479A (en) | 2022-06-10 |
| EP3793547A1 (en) | 2021-03-24 |
| GEP20227443B (en) | 2022-11-25 |
| AR115092A1 (es) | 2020-11-25 |
| CL2020002927A1 (es) | 2021-03-05 |
| KR20210010475A (ko) | 2021-01-27 |
| ZA202006327B (en) | 2022-06-29 |
| JOP20200276A1 (ar) | 2020-11-02 |
| EA202092586A1 (ru) | 2021-03-10 |
| MX2020012158A (es) | 2021-01-29 |
| SG11202011228TA (en) | 2020-12-30 |
| PH12020551934A1 (en) | 2021-06-21 |
| AU2019271123A1 (en) | 2020-11-26 |
| US10570106B2 (en) | 2020-02-25 |
| WO2019222266A1 (en) | 2019-11-21 |
| TW201946906A (zh) | 2019-12-16 |
| BR112020000863A2 (pt) | 2020-12-08 |
| US11332453B2 (en) | 2022-05-17 |
| US20210206735A1 (en) | 2021-07-08 |
| CO2020013550A2 (es) | 2020-11-10 |
| EP3793547A4 (en) | 2021-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021523200A (ja) | Ｍａｇｌ阻害剤 | |
| JP7042547B2 (ja) | Ｍａｇｌ阻害剤 | |
| JP6987859B2 (ja) | Ｍａｇｌ阻害剤 | |
| JP7042468B2 (ja) | Ｍａｇｌ阻害剤 | |
| JP7781660B2 (ja) | デュアルｍａｇｌ及びｆａａｈインヒビター | |
| JP2020532547A (ja) | スピロ環化合物並びにその作製及び使用方法 | |
| JP2021523902A (ja) | Ａｂｈｄ１２阻害剤並びにその製造及び使用方法 | |
| NZ753264B2 (en) | Magl inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20220428 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220513 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220513 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220428 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230530 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230525 |
|
| A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20230926 |